Lifitegrast is used to treat the signs and symptoms of Dry Eye Disease (DED). This therapeutic use is applied in contexts marked by increased discomfort or tension due to persistent inflammatory or irritative states associated with the condition.

---

Managing Conditions Characterized by Inflammation and Irritation

Xiidra is commonly used for conditions characterized by periods of heightened symptoms associated with Dry Eye Disease. It is applicable in clinical settings that involve persistent inflammatory or irritative states and is applied when appropriate. The medication helps address symptom clusters including grittiness, burning, stinging, and overall dryness.

“It is commonly used for conditions that present with disruptive symptom manifestations.”

---

Supportive Relief for Daily Ocular Function

The medication provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load of these irritating manifestations. The treatment may assist with maintaining functional stability by easing symptoms that disrupt clarity, such as blurring or fluctuating vision. This supports general well-being during symptomatic phases and contributes to improved comfort during periods when symptoms are more noticeable.

Quick Fact: Relief for Ocular Discomfort
The treatment is used for managing symptoms related to inflammatory or irritative states that create noticeable physiological strain on the eye.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Xiidra — official regulatory information

---

Eligibility scope

Classification	Population Group	Regulatory Status
Populations allowed	Adults and adolescents 17 years	Use is established
Populations contraindicated	Patients with known hypersensitivity to lifitegrast or any ingredient	Absolute prohibition
Age-related rules	Pediatric patients lt 17 years	Safety/efficacy not established
Physiological status	Pregnant or lactating women	No available human data
Condition-specific	Hepatic or renal impairment	No specific restrictions documented

---

Eligibility classifications (high-level)

Classification Type	Rule as Defined in Official Documents
Eligibility severity	Contraindicated (Hypersensitivity) and Use Not Established (Pediatric)
Eligibility-context	Contact lenses must be removed prior to administration for 15 minutes

---

Resulting eligibility structure

Official eligibility statements:

• Xiidra is contraindicated in patients with a known hypersensitivity to the active substance or its excipients.
• Safety and effectiveness have not been established in pediatric patients under 17 years of age.
• There are no available human data to inform drug-associated risks during pregnancy or lactation.
• Contact lenses must be removed before use and reinserted 15 minutes later.

Connection to the overall eligibility profile: The official profile is defined by a single absolute contraindication related to hypersensitivity to the formulation's ingredients. Eligibility is established for adults and adolescents 17 years and older, with use formally classified as not established for younger children. Use during pregnancy and lactation is constrained by the absence of human data to determine risk.

Interactions with other medicines and products

The regulatory profile for Xiidra (lifitegrast ophthalmic solution) is characterized by a minimal risk of interactions with other medications, food, or alcohol. This is due to the drug’s low systemic absorption following topical ocular administration.

Systemic Drug-Drug Interactions

Official regulatory documents state that no formal drug-drug interaction studies have been conducted for Xiidra, as its systemic exposure is low. This indicates that it is unlikely to have clinically significant interactions with systemically absorbed oral or injectable medications, including those that may affect CYP enzymes or common drug transporters.

Local and Procedural Interaction Requirements

Interactions are primarily restricted to administration practices involving other topical eye products and medical devices:

Substance / Condition	Required Action
Other Topical Ophthalmic Drugs	Wait at least 5 to 10 minutes between applications.
Contact Lenses	Must be removed prior to use and may be reinserted 15 minutes after administration.

Food, Alcohol, and Specific Populations

• Food, Alcohol, or Herbal Products: No known interactions are documented in regulatory labeling.
• Population Notes: No specific interaction considerations are listed for elderly patients or those with hepatic or renal impairment, consistent with the minimal systemic exposure.

Targeted Blockade of Immune Cell Adhesion (LFA-1 Antagonism)

The core mechanism involves the active ingredient, lifitegrast, which functions as a competitive antagonist against the integrin protein Lymphocyte Function-Associated Antigen-1 (LFA-1) found on the surface of T-cells. Lifitegrast binds directly to LFA-1, physically blocking the interaction with its partner protein, Intercellular Adhesion Molecule-1 (ICAM-1), which is often overexpressed on ocular surface cells. This key blockade inhibits the ability of T-cells to adhere and migrate to the affected tissue, thereby contributing to the modulation of the inflammatory cascade.

Suppression of Ocular Inflammatory Cascades

By disrupting the LFA-1/ICAM-1 interaction, lifitegrast interferes with the formation of the immunological synapse, which is necessary for T-cell activation and communication. This cellular interference leads to a reduction in the secretion of pro-inflammatory cytokines by the immune cells. This targeted suppression of the chemical signals and reduction in immune cell infiltration leads to a diminution of chronic, localized inflammatory activity on the corneal and conjunctival surfaces.

Mechanistic Specificity and Limitations

While the LFA-1 antagonism is defined, authoritative scientific documents note that the precise, full mechanism of action of lifitegrast in the complex pathophysiology of the condition is not fully known. Furthermore, the mechanism is primarily relevant in inflammation that is LFA-1/ICAM-1 mediated, indicating its mechanistic specificity to those processes.

How to use Xiidra

The use of Xiidra (lifitegrast 5% ophthalmic solution) follows a precise, standardized regimen. Administration is limited to the topical ocular route, requiring one drop to be instilled into each affected eye as part of a continuous protocol.

The dosing frequency is twice daily, and the two applications should be separated by approximately 12 hours to maintain a consistent dosing interval throughout the day. The medication is supplied in single-use containers, and the content of one container provides one complete dose for both eyes. To uphold sterility and integrity, the container, including any remaining solution, must be discarded immediately after a single administration and cannot be saved for later use.

Specific procedural constraints apply to proper application. Individuals who wear contact lenses must remove them prior to use and wait at least 15 minutes before reinserting them. The safety and effectiveness of this regimen have not been established for patients under 17 years of age. In the event of a missed dose, the instruction is to skip the missed application if it is near the time for the next dose; the use of a double dose is prohibited. This composite set of requirements establishes the formal, non-cyclical protocol for the drug's administration.

Research Evidence / Overview of Studies for Xiidra

Evidence Supporting Use in Dry Eye Disease

The core research base for lifitegrast (Xiidra) was evaluated in studies exploring conditions characterized by fluctuating or episodic manifestations of Dry Eye Disease (DED). This evidence relies primarily on short-term, randomized, controlled trials (RCTs). These pivotal studies, typically lasting 12 weeks, included large groups of adult participants and compared the active compound against a vehicle (a non-medicated drop used as a control).

In these trials, researchers monitored two main types of outcomes: patient-reported experiences (symptoms) and objective clinical signs. Patient-reported scores, such as the Eye Dryness Score (EDS), were used in research exploring short-term symptom changes. Findings describe patterns observed in the studies for how symptoms evolved in the observed populations when compared to the control group.

Study Designs and Measurements Used

The controlled study designs utilized objective clinical assessments, such as the Inferior Corneal Staining Score (ICSS), a physician-graded measure of damage to the eye's surface, as well as the subjective EDS. The research examined patterns related to symptom intensity or variability and generally monitored patient responses over defined time intervals of 84 days.

Long-Term Evidence and Follow-up

The primary endpoints in the core clinical trials were assessed over follow-up durations that were limited to 12 weeks. This means that information on long-term outcomes is not fully established based on the highest level of controlled evidence. Subsequent observational studies and retrospective reviews have explored patterns of administration in settings evaluating daily-life functioning beyond the initial three months.

Research Gaps and Areas of Uncertainty

The evidence base presents several research limitation frames. Findings for the objective clinical sign measurement (ICSS) were mixed across the four main trials, unlike the more consistent findings for the patient-reported symptom score. The research suggests the need for continued study to better understand the correlation between the measured signs and the patient's perceived discomfort. Data for certain groups, such as children or older adults over 75, remain insufficient as the studies were evaluated in a broad adult population.

Common questions about Xiidra (FAQ)

---

Q: What is the full list of ingredients in Xiidra eye drops?

The active ingredient in Xiidra is lifitegrast. According to the official product information, the inactive ingredients, also known as excipients, include sodium chloride, sodium phosphate dibasic anhydrous, sodium thiosulfate pentahydrate, sodium hydroxide and/or hydrochloric acid, and water for injection. These ingredients are necessary to maintain the solution's stability and correct formulation.

---

Q: What is the maximum age or population group for whom safety data is lacking?

Regulatory information indicates that Xiidra has been studied in a broad adult population, which included patients up to 97 years of age in clinical trials. No overall differences in the effectiveness or safety profile were specifically observed between older and younger adult patients. Official safety information for patients under 17 years of age remains not established.

---

Q: Can I use Xiidra while pregnant or breastfeeding?

Official regulatory documents state that there are no adequate and well-controlled human studies available for Xiidra use during pregnancy. Since the systemic exposure of the drug is low after topical use, use during pregnancy is generally considered only when the potential benefit is clearly necessary. Furthermore, it is currently unknown whether the medication passes into human milk during breastfeeding.

---

Q: How long does it take for Xiidra to start working?

Clinical trial data referenced in the drug's official label suggests that some patients may experience initial symptom improvement (Eye Dryness Score) as early as two weeks of continuous use. Individual patient response may vary, and the full therapeutic benefit may take longer than this initial period.

---

Q: How long can the unopened foil pouch be stored?

Xiidra single-use containers are supplied in foil pouches and should be kept in the original pouch until use to protect the medicine from light. The expiration date is printed on the carton and foil pouch and indicates the maximum storage period.

---

Q: Is Xiidra available as a generic drug?

Currently, Xiidra is only available as a brand-name prescription medication containing the active ingredient lifitegrast. According to regulatory status information, there is no generic version of Xiidra approved or available for marketing at this time.

---

Q: Does Xiidra cause weight gain?

Official product information, which includes a comprehensive list of common adverse reactions reported in clinical trials, does not list weight gain as a reported side effect. The most common non-ocular side effect experienced by patients is an unusual taste sensation, known medically as dysgeusia.

---

Q: Is Xiidra used for purposes other than dry eye disease (off-label uses)?

The medication is approved by regulatory bodies, such as the FDA, for the treatment of the signs and symptoms of dry eye disease (DED). Official prescribing information only discusses the use of the drug for this approved indication.

How to Store and Dispose of Xiidra

Xiidra (lifitegrast ophthalmic solution) must be stored and handled according to specific conditions to maintain its quality, as required by regulatory labeling.

---

Storage and Handling

Condition	Requirement (Official Labeling)
Temperature	Store at room temperature (68 F to 77 F or 20 C to 25 C). Do not freeze.
Protection	Keep the single-use containers in the original foil pouch to protect from light, heat, and moisture.
Child Safety	Keep the medicine out of the reach of children.
Stability Limit	The opened single-use container must be discarded immediately after use in each eye.

---

Disposal Instructions

Unused or expired Xiidra should be disposed of by consulting a pharmacist or healthcare professional for guidance. The medicine should not be thrown in household trash or down the toilet, as per general safety guidelines for pharmaceutical waste.